Mark Verdi - Genpact Independent Director
| G Stock | USD 30.89 0.33 1.08% |
Director
Mr. Mark A. Verdi is an Independent Director of Genpact Limited. Partner, AVALT Holdings, President, CS Wholesale Grocers, Inc., Managing Director, Bain Capital, Head of financial services business transformation outsourcing group, IBM Global Services, Burlington Stores, Inc. Trinseo S.A. Bloomin Brands, Inc. since 2012.
| Age | 54 |
| Tenure | 12 years |
| Address | Canon's, Court, Hamilton, Bermuda, HM 12 |
| Phone | 441 298 3300 |
| Web | https://www.genpact.com |
Genpact Management Efficiency
The company has return on total asset of 0.083 % which means that for every 100 dollars spent on assets, it generated a profit of $0.083. This is way below average. Similarly, it shows a return on equity (ROE) of 0.3099 %, implying that it made 0.3099 on every $100 invested by shareholders. Genpact's management efficiency ratios could be used to measure how well Genpact manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Genpact's Return On Equity is most likely to increase slightly in the upcoming years. At this time, Genpact's Intangibles To Total Assets are most likely to slightly decrease in the upcoming years. The Genpact's current Return On Assets is estimated to increase to 0.14, while Other Assets are projected to decrease to 0.95.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Marc Holtzman | TTEC Holdings | 58 | |
| Tracy Bahl | TTEC Holdings | 56 | |
| Paul Levi | Science Applications Internatio | N/A | |
| Barry Allen | CDW Corp | 69 | |
| Gary Wimberly | Perficient | 57 | |
| James Bell | CDW Corp | 69 | |
| William Jews | CACI International | 68 | |
| Steven Anenen | TTEC Holdings | 65 | |
| Garth Graham | Science Applications Internatio | 45 | |
| John Hamre | Science Applications Internatio | 69 | |
| Marie Joliet | ASGN Inc | 49 | |
| Nitin Sahney | ExlService Holdings | 55 | |
| Gregory Conley | TTEC Holdings | 63 | |
| Joseph Swedish | CDW Corp | 66 | |
| Benjamin Chereskin | CDW Corp | 59 | |
| William Wallace | CACI International | 73 | |
| Edwin Sheridan | ASGN Inc | 50 | |
| Warren Phillips | CACI International | 78 | |
| David Lundeen | Perficient | 56 | |
| Virginia Addicott | CDW Corp | 54 | |
| David Kelso | ExlService Holdings | 65 | |
Management Performance
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.083 |
Genpact Limited Leadership Team
Elected by the shareholders, the Genpact's board of directors comprises two types of representatives: Genpact inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Genpact. The board's role is to monitor Genpact's management team and ensure that shareholders' interests are well served. Genpact's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Genpact's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Piyush Mehta, Chief Human Resources Officer, Senior Vice President | ||
| Edward Fitzpatrick, Chief Financial Officer, Senior Vice President | ||
| CFA CFA, VP CFO | ||
| Carol Lindstrom, Independent Director | ||
| Kathryn Stein, Senior Vice President, Chief Strategy Officer and Global Business Leader, Enterprise Services | ||
| Edward CPA, Senior Advisor | ||
| Nallicheri Tyagarajan, CEO President | ||
| Krista Bessinger, Head Relations | ||
| Jim Madden, Independent Director | ||
| Brian Stevens, Independent Director | ||
| CeCe Morken, Director | ||
| Kevin Webb, Head Services | ||
| Michael CFA, Senior CFO | ||
| Laura Conigliaro, Independent Director | ||
| Tamara Franklin, Independent Director | ||
| Ezra Baylin, Head Acquisitions | ||
| Hailey Eichner, Chief CEO | ||
| Victor Guaglianone, Senior Vice President General Counsel, Corporate Secretary | ||
| CeCelia Morken, Independent Director | ||
| Mark Verdi, Independent Director | ||
| Vipin Gairola, Global Officer | ||
| Hanspeter Spek, Independent Director | ||
| Darren Saumur, Senior Vice President Global Operating Officer | ||
| Sameer Dewan, Senior Leader | ||
| Patrick Cogny, Senior Vice President - Infrastructure, Manufacturing & Services and High Tech | ||
| Robert Scott, Independent Non-Executive Chairman of the Board | ||
| Mohit Thukral, Sr. VP of Banking, Financial Services and Insurance | ||
| Ahmed Mazhari, Senior Vice President Chief Growth Officer | ||
| Ajay Agrawal, Independent Director | ||
| Michael Weiner, Chief Financial Officer, Senior Vice President | ||
| Roger CFA, Head Relations | ||
| Alex Mandl, Independent Director | ||
| Balkrishan Kalra, Senior Vice President - Banking, Capital Markets, Consumer Goods, Retail, Life Sciences and Healthcare | ||
| Heather White, Senior Vice President, Chief Legal Officer, Corporate Secretary | ||
| Vidya Rao, Chief Officer | ||
| N Tyagarajan, President, Chief Executive Officer, Director | ||
| Anil Nanduru, Consumer Manufacturing | ||
| Stacey Cartwright, Independent Director | ||
| Donald Klunk, Chief Officer | ||
| Mohit Bhatia, Sr. VP and Internal Transformation Leader | ||
| Rajiv Naidu, Business Affairs | ||
| Mark Nunnelly, Independent Director | ||
| James Madden, Non-Executive Independent Chairman of the Board | ||
| Caitlin Blewett, Chief Officer | ||
| Riju Vashisht, Chief Officer | ||
| Arvinder Singh, Sr. VP and Bus. Leader of Capital Markets and IT Services | ||
| Amit Chandra, Independent Director | ||
| David Humphrey, Independent Director |
Genpact Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Genpact a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.31 | ||||
| Return On Asset | 0.083 | ||||
| Profit Margin | 0.14 % | ||||
| Operating Margin | 0.14 % | ||||
| Current Valuation | 6.45 B | ||||
| Shares Outstanding | 180.33 M | ||||
| Shares Owned By Insiders | 1.00 % | ||||
| Shares Owned By Institutions | 98.99 % | ||||
| Number Of Shares Shorted | 4.42 M | ||||
| Price To Earning | 28.59 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Genpact Limited. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Genpact Limited information on this page should be used as a complementary analysis to other Genpact's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.
Complementary Tools for Genpact Stock analysis
When running Genpact's price analysis, check to measure Genpact's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genpact is operating at the current time. Most of Genpact's value examination focuses on studying past and present price action to predict the probability of Genpact's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genpact's price. Additionally, you may evaluate how the addition of Genpact to your portfolios can decrease your overall portfolio volatility.
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |
Is Genpact's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Genpact. If investors know Genpact will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Genpact listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 2.311 | Dividend Share 0.55 | Earnings Share 3.41 | Revenue Per Share 24.552 | Quarterly Revenue Growth 0.04 |
The market value of Genpact Limited is measured differently than its book value, which is the value of Genpact that is recorded on the company's balance sheet. Investors also form their own opinion of Genpact's value that differs from its market value or its book value, called intrinsic value, which is Genpact's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Genpact's market value can be influenced by many factors that don't directly affect Genpact's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Genpact's value and its price as these two are different measures arrived at by different means. Investors typically determine if Genpact is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Genpact's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.